Rix U - Search Results

1

Polypharmacology-based ceritinib repurposing using integrated functional proteomics.

Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U. Kuenzi BM, et al. Among authors: rix u. Nat Chem Biol. 2017 Dec;13(12):1222-1231. doi: 10.1038/nchembio.2489. Epub 2017 Oct 9. Nat Chem Biol. 2017. PMID: 28991240 Free PMC article.

2

The dynamic structure of jadomycin B and the amino acid incorporation step of its biosynthesis.

Rix U, Zheng J, Remsing Rix LL, Greenwell L, Yang K, Rohr J. Rix U, et al. J Am Chem Soc. 2004 Apr 14;126(14):4496-7. doi: 10.1021/ja031724o. J Am Chem Soc. 2004. PMID: 15070349

3

The oxidative ring cleavage in jadomycin biosynthesis: a multistep oxygenation cascade in a biosynthetic black box.

Rix U, Wang C, Chen Y, Lipata FM, Remsing Rix LL, Greenwell LM, Vining LC, Yang K, Rohr J. Rix U, et al. Chembiochem. 2005 May;6(5):838-45. doi: 10.1002/cbic.200400395. Chembiochem. 2005. PMID: 15776503 No abstract available.

4

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G. Rix U, et al. Blood. 2007 Dec 1;110(12):4055-63. doi: 10.1182/blood-2007-07-102061. Epub 2007 Aug 24. Blood. 2007. PMID: 17720881 Free article.

5

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G. Remsing Rix LL, et al. Among authors: rix u. Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27. Leukemia. 2009. PMID: 19039322

6

Target profiling of small molecules by chemical proteomics.

Rix U, Superti-Furga G. Rix U, et al. Nat Chem Biol. 2009 Sep;5(9):616-24. doi: 10.1038/nchembio.216. Nat Chem Biol. 2009. PMID: 19690537 Review.

7

A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.

Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G. Rix U, et al. Leukemia. 2010 Jan;24(1):44-50. doi: 10.1038/leu.2009.228. Epub 2009 Nov 5. Leukemia. 2010. PMID: 19890374

8

Dasatinib in solid tumors.

Kim LC, Rix U, Haura EB. Kim LC, et al. Among authors: rix u. Expert Opin Investig Drugs. 2010 Mar;19(3):415-25. doi: 10.1517/13543781003592097. Expert Opin Investig Drugs. 2010. PMID: 20113198 Review.

9

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.

Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. Li J, et al. Among authors: rix u. Nat Chem Biol. 2010 Apr;6(4):291-9. doi: 10.1038/nchembio.332. Epub 2010 Feb 28. Nat Chem Biol. 2010. PMID: 20190765 Free PMC article.

10

MASPECTRAS 2: An integration and analysis platform for proteomic data.

Ubaida Mohien C, Hartler J, Breitwieser F, Rix U, Remsing Rix L, Winter GE, Thallinger GG, Bennett KL, Superti-Furga G, Trajanoski Z, Colinge J. Ubaida Mohien C, et al. Among authors: rix u. Proteomics. 2010 Jul;10(14):2719-22. doi: 10.1002/pmic.201000075. Proteomics. 2010. PMID: 20455215

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters